Kynamro FDA Approval History
FDA Approved: Yes (Discontinued) (First approved January 29, 2013)
Brand name: Kynamro
Generic name: mipomersen
Dosage form: Injection
Company: Kastle Therapeutics
Treatment for: High Cholesterol, Familial Homozygous
Marketing Status: Discontinued
Kynamro (mipomersen) is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated for the treatment of patients with homozygous familial hypercholesterolemia.
Development timeline for Kynamro
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.